Gongwin Biopharm (共信-KY) presented clinical data for its developmental equine drug, p-TLS, at the 2026 World Equine Veterinary Association (WEVA) Congress. The drug, targeting superficial tumors such as melanomas, squamous cell carcinomas, and sarcomas, demonstrated a 100% tumor ablation rate.
Read more
